#USA #Plymouth Meeting #NCCN #Cancer #Nancy Lewis

Nancy L. Lewis, MD, MBS, FACP, New Chief Scientific Officer for NCCN

The National Comprehensive Cancer Network (NCCN), known for its commitment to enhancing cancer care, has appointed Dr. Nancy L. Lewis as its new Chief Scientific Officer. Dr. Lewis's extensive background in biomedical research positions her ideally to lead critical initiatives aimed at advancing clinical trials and improving the efficacy and accessibility of cancer treatments.

A Proven Track Record in Cancer Research

Dr. Lewis brings a wealth of experience to her new role, having served as the Senior Clinical Program Leader at Novartis Pharmaceuticals. Prior to her tenure at Novartis, she was an Associate Professor at various prestigious academic institutions specializing in cancer research. Dr. Lewis completed her education with degrees from esteemed institutions such as Penn State University and Temple University School of Medicine, bolstered by residency training at the University of Rochester and a fellowship at the Fox Chase Cancer Center, which is one of the founding members of NCCN.

The appointment comes at a crucial time in the landscape of cancer research, which is evolving rapidly. Dr. Crystal S. Denlinger, CEO of NCCN, stated, "We have made significant strides, but we have a long journey ahead. Dr. Lewis is uniquely equipped to guide our efforts to drive innovation and discovery that can profoundly impact the lives of cancer patients."

Enhancing Cancer Care programs

In her capacity as Chief Scientific Officer, Dr. Lewis will oversee critical components of the NCCN Oncology Research Program, focusing on enhancing clinical practices as outlined in the NCCN Clinical Practice Guidelines in Oncology. Additionally, her role includes managing the NCCN Biomarkers Compendium, Radiation Therapy Compendium, and ensuring that the Imaging Appropriate Use Criteria are up-to-date.

Furthermore, Dr. Lewis will play an integral role in continuing medical education programs and various global health ownership initiatives. Her proactive approach aims to ensure that NCCN continues to be at the forefront of providing evidence-based patient care guidelines, enabling both healthcare providers and patients to be well-informed.

Recognition and Awards

Dr. Lewis is recognized within the scientific community, having received accolades from prominent organizations including the American Association for Cancer Research, the American Society of Clinical Oncology, and the American Cancer Society. These awards underline her contributions to oncological research and embody her leadership capabilities in the evolving field of cancer treatment.

Looking Forward

Expressing her enthusiasm, Dr. Lewis said, "I am honored to take on this role within the NCCN, an organization with a remarkable legacy of promoting high-quality cancer care. I look forward to collaborating with inspiring colleagues to confront the significant challenges we face and uncover innovative solutions that can improve patients' lives."

In assuming her role in May 2026, Dr. Lewis will take over responsibilities previously held by Dr. Denlinger, who is now the CEO of NCCN. This transition marks a new chapter for both Dr. Lewis and the organization as they continue to confront the complexities of cancer treatment.

The NCCN, as a not-for-profit alliance of leading cancer centers, underscores its dedication to advancing effective, equitable, and accessible cancer care, ultimately aspiring for better health outcomes for all individuals affected by cancer. For more information, visit NCCN.org.